ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2012
The role of nuclear medicine in modern therapy of cancer.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 55 citations in OpenAlex.
- The Increasing Importance of Breast Cancer in the United Arab Emirates.Asia-Pacific journal of clinical oncology · 2026Review
- Review
- Preclinical Aspects of [Current radiopharmaceuticals · 2025Article
- Chelation of [Dalton transactions (Cambridge, England : 2003) · 2024Article
- Actinium chelation and crystallization in a macromolecular scaffold.Nature communications · 2024Article
- Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma.Pharmaceuticals (Basel, Switzerland) · 2023Review
- SPECT Imaging with Tc-99m-Labeled HYNIC-FAPI-04 to Extend the Differential Time Window in Evaluating Tumor Fibrosis.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents.International journal of nanomedicine · 2023Review
- Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges.Molecules (Basel, Switzerland) · 2022Review
- Chelating Rare-Earth Metals (LnInorganic chemistry · 2022Article
- Therapeutic effect of antihypertensive drug on diabetic nephropathy: Functional and structural kidney investigation.Saudi journal of biological sciences · 2022Article
- Ewing's sarcoma of the hip: A case report with no evidence of tumor recurrence and literature review.Bone reports · 2021Article
- Development of Radiotracers for Breast Cancer-The Tumor Microenvironment as an Emerging Target.Cells · 2020Review
- Evaluation ofArthritis research & therapy · 2018Article
- Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody.Molecular imaging and biology · 2018Article
- Imaging Considerations and Interprofessional Opportunities in the Care of Breast Cancer Patients in the Neoadjuvant Setting.Seminars in oncology nursing · 2017Review
- Theranostics in nuclear medicine practice.OncoTargets and therapy · 2017Review
- Gold nanorod-mediated hyperthermia enhances the efficacy of HPMA copolymer-90Y conjugates in treatment of prostate tumors.Nuclear medicine and biology · 2014Article
- Prognostic significance of sphingosine kinase 2 expression in non-small cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- High expression of M3 muscarinic acetylcholine receptor is a novel biomarker of poor prognostic in patients with non-small cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nuclear medicine is a multidisciplinary field that develops and uses instrumentation and tracers (radiopharmaceuticals) to study physiological processes and noninvasively diagnose, stage, and treat diseases. Particularly, it offers a unique means to study cancer biology in vivo and to optimize cancer therapy for individual patients. A tracer is either a radionuclide alone, such as iodine-131 or a radiolabel in a carrier molecule such as (18)F in fluorodeoxyglucose ((18)F-FDG), or other feasible radionuclide attached to a drug, a protein, or a peptide, which when introduced into the body, would accumulate in the tissue of interest. Nuclear medicine imaging, including single-photon emission computer tomography and positron emission tomography, can provide important quantitative and functional information about normal tissues or disease conditions, in contrast to conventional, anatomical imaging techniques such as ultrasound, computed tomography, or magnetic resonance imaging. For treatment, tumor-targeting agents, conjugated with therapeutic radionuclides, may be used to deposit lethal radiation at tumor sites. This review outlines the role of nuclear medicine in modern cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.